AbClon Inc.
Financials
Valuation Metrics
AbClon Inc.'s Market Cap is ₩3669B. At end of 2025 it was ₩8480B. Ranked #535 of 2,410 in KR market (top 22%), #210 of 1,631 on KOSDAQ (top 13%), #56 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 24%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 366.92B KRW | KR#535/2,410 Sec#56/231 |
| Revenue | 5.31B KRW | KR#2,327/2,410 Sec#194/231 |
| Net Income | -17.30B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 64.50B KRW | KR#2,059/2,410 Sec#176/231 |
| Net Assets | 53.07B KRW | KR#1,866/2,410 Sec#159/231 |
| Employees | 63 | KR#1,934/2,410 Sec#171/231 |
| Value | ||
| P/B | 6.91x | KR#2,320/2,410 Sec#202/231 |
| P/S | 69.13x | KR#2,375/2,410 Sec#205/231 |
| FCF Yield | -3.93% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -32.60% | KR#2,195/2,410 Sec#182/231 |
| ROA | -26.82% | KR#2,285/2,410 Sec#194/231 |
| Op. Margin | -336.22% | KR#2,339/2,410 Sec#196/231 |
| Revenue Growth | 75.02% | KR#127/2,410 Sec#20/231 |
| Financial Health | ||
| Debt Ratio | 21.54% | KR#402/2,410 Sec#49/231 |
| Total Debt | 7.00B KRW | KR#1,714/2,410 Sec#159/231 |
| FCF | -14.42B KRW | KR#1,802/2,410 Sec#167/231 |
| Cash | 30.38B KRW | KR#1,005/2,410 Sec#68/231 |
| Current Ratio | 3.89x | KR#400/2,410 Sec#63/231 |
| Performance | ||
| 1Y Return | -15.25% | KR#892/2,410 Sec#56/231 |
| 1M Return | -34.09% | KR#1,793/2,410 Sec#175/231 |
| From 52W High | -80.80% | KR#2,302/2,410 Sec#211/231 |
| 1Y MDD | -81.12% | KR#2,302/2,410 Sec#208/231 |
| Trading | ||
| Volume | 60,002 shares | KR#327/2,410 Sec#32/231 |
| Trading Value | 1.11B KRW | KR#305/2,410 Sec#29/231 |
| Foreign Own. | 7.73% | KR#574/2,410 Sec#47/231 |
| Per Share | ||
| EPS | -867 KRW | KR—/2,410 Sec—/231 |
| BPS | 2,660 KRW | KR#1,939/2,410 Sec#152/231 |
Company Info
AbClon, established in 2010 and headquartered in Guro-gu, Seoul, is a bio-venture focused on antibody new drug development, manufacturing, and sales, specially listed on KOSDAQ in 2017. The company utilizes platforms such as NEST, AffiMab, and CAR-T, maintaining a research network with Atlas in Sweden. AbClon licensed AC101, developed with NEST technology, to Shanghai Henlius, and its CAR-T therapeutic AT101 is currently in Phase 2 clinical trials. It aims to strengthen its immune cell therapy presence through a partnership with Chong Kun Dang in 2025.